{"organizations": [], "uuid": "6487d546eeb35a2351f16a384223c741d6e3ae9f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-inventiva-fy-revenues-down-31-perc/brief-inventiva-fy-revenues-down-31-percent-idUSFWN1Q21B6", "country": "US", "domain_rank": 408, "title": "BRIEF-Inventiva FY Revenues Down 31 Percent", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.025, "site_type": "news", "published": "2018-02-13T01:26:00.000+02:00", "replies_count": 0, "uuid": "6487d546eeb35a2351f16a384223c741d6e3ae9f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-inventiva-fy-revenues-down-31-perc/brief-inventiva-fy-revenues-down-31-percent-idUSFWN1Q21B6", "ord_in_thread": 0, "title": "BRIEF-Inventiva FY Revenues Down 31 Percent", "locations": [], "entities": {"persons": [{"name": "inventiva", "sentiment": "negative"}], "locations": [{"name": "australia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - INVENTIVA SA:\n* FULL-YEAR 2017 FINANCIAL INFORMATION AND BUSINESS UPDATE\n* ‍FY REVENUES OF EUR 6.5 MILLION, A 31% DECREASE COMPARED TO 2016​\n* ‍CASH AND CASH EQUIVALENT LEVEL AT EUR 59 MILLION AS OF DECEMBER 31, 2017​\n* ‍NATIVE HEADLINE RESULTS ANTICIPATED SECOND-HALF OF 2019, VERSUS PREVIOUS EXPECTATIONS FOR EARLY 2019\n* PARTNERSHIP WITH ABBVIE PROGRESSING ACCORDING TO PLAN​ * ON ABBVIE PARTNERSHIP, SAYS NEW CLINICAL CANDIDATE ABBV-157 EXPECTED TO ENTER INTO CLINICAL DEVELOPMENT IN 2018\n* YAP-TEAD PROGRAM EXPECTED TO ENTER INTO PHASE I-ENABLING PRECLINICAL DEVELOPMENT IN 2019\n* ON ODIPARCIL PROGRAM: DATA CURRENTLY BEING ANALYSED AND RESULTS EXPECTED TO BE PUBLISHED IN H1 2018\n* ON LANIFIBRANOR PROGRAM : HEADLINE RESULTS ANTICIPATED SECIN H2 2019, VERSUS PREVIOUS GUIDANCE OF EARLY 2019.\n* ON LANIFIBRANOR PROGRAM : COMPLETION OF PATIENT ENROLLMENT, NOW EXPECTED BY END OF 2018\n* ON LANIFIBRANOR PROGRAM : TWO NEW COUNTRIES HAVE BEEN OPENED (CANADA AND AUSTRALIA)\n* ON LANIFIBRANOR PROGRAM : TWO ADDITIONAL COUNTRIES ARE ALSO IN THE PROCESS OF JOINING TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T01:26:00.000+02:00", "crawled": "2018-02-13T15:58:48.000+02:00", "highlightTitle": ""}